Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

38.83 +0.23 (+0.61%)

Delayed Quote Updated: 12:20 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why Is Sleep Disorder Related Harmony Biosciences Stock Trading Lower Today? ↗

October 13, 2023

Harmony Biosciences Holdings Inc (NASDAQ: HRMY) announced topline results from the INTUNE Phase 3 study of pitolisant in patients with idiopathic hypersomnia (IH).

Via Benzinga

In the world of growth stocks, NASDAQ:HRMY shines as a value proposition. ↗

October 12, 2023

NASDAQ:HRMY, a growth stock which is not overvalued.

Via Chartmill

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies ↗

October 11, 2023

Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc.

Via Benzinga

2 Magnificent Growth Stocks to Buy Right Now ↗

October 04, 2023

These two biotech stocks could be big winners for patient investors.

Via The Motley Fool

Expert Ratings for Harmony Biosciences ↗

September 25, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗

September 25, 2023

Via Benzinga

9 Analysts Have This to Say About Harmony Biosciences ↗

September 07, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023 ↗

September 07, 2023

Via Benzinga

Expert Ratings for Harmony Biosciences ↗

August 22, 2023

Via Benzinga

The Latest Analyst Ratings for Harmony Biosciences ↗

August 01, 2023

Via Benzinga

Harmony Biosciences's Earnings Outlook ↗

July 31, 2023

Via Benzinga

Analyst Expectations for Harmony Biosciences's Future ↗

June 23, 2023

Via Benzinga

ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE

August 17, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

NASDAQ: HRMY Investor Alert: Investigation over Potential Wrongdoing at Harmony Biosciences Holdings, Inc. ↗

August 17, 2023

San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc.

Via SBWire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID)

August 14, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Harmony Biosciences Earnings Perspective: Return On Capital Employed ↗

May 08, 2023

Via Benzinga

Analyst Expectations for Harmony Biosciences's Future ↗

May 03, 2023

Via Benzinga

Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher ↗

August 14, 2023

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The...

Via Benzinga

Topics Stocks

Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today? ↗

August 14, 2023

With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications.

Via InvestorPlace

Health Care Company Harmony Biosciences Announces Acquisition of Zynerba Pharmaceuticals ↗

August 14, 2023

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

August 14, 2023

Via Benzinga

Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today? ↗

August 14, 2023

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares are skyrocketing Monday after Harmony Biosciences (NASDAQ: HRMY) announced it will

Via Benzinga

7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now ↗

August 03, 2023

Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts.

Via InvestorPlace

Harmony Biosciences (HRMY) Q2 2023 Earnings Call Transcript ↗

August 01, 2023

HRMY earnings call for the period ending June 30, 2023.

Via The Motley Fool

Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates

August 01, 2023

From Harmony Biosciences

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 24, 2023

Via Benzinga

7 Best High-Growth Stocks to Buy if You’re a Young Investor ↗

June 29, 2023

If you’re just starting out and have plenty of time to work with, these are the high-growth stocks for young investors.

Via InvestorPlace

3 Biotech Stocks to Buy With Explosive Upside Potential ↗

June 22, 2023

These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.

Via InvestorPlace

Bragar Eagel & Squire, P.C. Is Investigating Techtronic, Boxed, Coinbase, and Harmony and Encourages Investors to Contact the Firm

June 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Harmony Biosciences (HRMY) Q1 2023 Earnings Call Transcript ↗

May 02, 2023

HRMY earnings call for the period ending March 31, 2023.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.